首页> 外文OA文献 >PND25 Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Compared To Glatiramer Acetate And Fingolimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

【2h】

PND25 Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Compared To Glatiramer Acetate And Fingolimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

机译：延迟释放富马酸二甲酯与醋酸格拉替雷和芬戈莫德相比延缓释放多发性硬化症的成本效益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Mauskopf J.A.; Fay M.; Iyer R.; Livingston T.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. THE COST-EFFECTIVENESS OF DELAYED-RELEASE DIMETHYL FUMARATE VERSUS GLATIRAMER ACETATE FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE CHILEAN NATIONAL HEALTH FUND (FONASA) [J] . Noda C., de Anda J. A., Anaya P., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：延缓释放富马酸二甲酯对乙酸格拉酯治疗智利国家卫生基金（FONASA）缓解多发性硬化症的成本效益
2. Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis [J] . Jonathan Calkwood, Mark Novas, Ray Zhang, International journal of MS care . 2016,第3期

机译：延缓释放富马酸二甲酯与干扰素β或醋酸格拉替雷在复发性多发性硬化症中的安全性和耐受性
3. DELAYED-RELEASE DIMETHYL FUMARATE DEMONSTRATED NO DIFFERENCE IN CLINICAL OUTCOMES VERSUS FINGOLIMOD IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS: RESULTS FROM THE REAL-WORLD EFFECT STUDY [J] . Sloane Jacob, Phillips J. Theodore, Calkwood Jonathan, Journal of Neurology, Neurosurgery and Psychiatry . 2018,第6期

机译：延迟释放二甲基富马酸盐证明临床结果对慢性多发性硬化症患者的临床结果与Fingolimod的差异显示：现实世界效应研究的结果
4. Microstructural Modulations in the Hippocampus Allow to Characterizing Relapsing-Remitting Versus Primary Progressive Multiple Sclerosis [C] . Lorenza Brusini, Ilaria Boscolo Galazzo, Muge Akinci, International Workshop on Brain-Lesion;Medical Image Computing and Computer Assisted Intervention Conference . 2020

机译：海马中的微观结构调制允许表征复发 - 延长与初级进步多发性硬化
5. Cost-Effectiveness of Oral Agents in Relapsing-Remitting Multiple Sclerosis Compared to Interferon-Based Therapy in Saudi Arabia [D] . Alskaabi, May. 2017

机译：沙特阿拉伯口服药物在复发缓解型多发性硬化症中的成本效果与基于干扰素的疗法相比
6. Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis [O] . Jonathan Calkwood, Timothy Vollmer, Robert J. Fox, 2016

机译：延缓释放富马酸二甲酯与干扰素β或醋酸格拉替雷在复发性多发性硬化症中的安全性和耐受性
7. PND10 Comparative Effectiveness Using A Matching-Adjusted Indirect Comparison Between Delayed-Release Dimethyl Fumarate and Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis [O] . Fox RJ, Cutter G, Chan A, 2015

机译：使用延缓释放的富马酸二甲酯和芬戈莫德的匹配调整间接比较对PND10的疗效比较，用于复发性多发性硬化症的治疗

PND25 Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Compared To Glatiramer Acetate And Fingolimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

著录项

引文网络

相似文献

相关主题

期刊订阅